Brainstorm Cell Therapeutics (BCLI) Short Interest Ratio & Short Volume $1.20 0.00 (0.00%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.20 0.00 (-0.42%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Brainstorm Cell Therapeutics Short Interest DataBrainstorm Cell Therapeutics (BCLI) has a short interest of 604,500 shares, representing 7.91% of the float (the number of shares available for trading by the public). This marks a 30.48% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 400,128 shares to cover all short positions.Current Short Interest604,500 sharesPrevious Short Interest463,300 sharesChange Vs. Previous Month+30.48%Dollar Volume Sold Short$677.04 thousandShort Interest Ratio0.4 Days to CoverLast Record DateJune 30, 2025Outstanding Shares9,840,000 sharesFloat Size7,640,000 sharesShort Percent of Float7.91%Today's Trading Volume187,564 sharesAverage Trading Volume400,128 sharesToday's Volume Vs. Average47% Short Selling Brainstorm Cell Therapeutics? Sign up to receive the latest short interest report for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartBCLI Short Interest Over TimeBCLI Days to Cover Over TimeBCLI Percentage of Float Shorted Over Time Brainstorm Cell Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/2025604,500 shares $677.04 thousand +30.5%7.9%0.4 $1.12 6/15/2025463,300 shares $509.63 thousand -13.7%7.5%0.4 $1.10 5/31/2025536,900 shares $617.33 thousand +156.3%8.7%0.4 $1.15 5/15/2025209,500 shares $243.02 thousand -28.1%3.4%0.2 $1.16 4/30/2025291,400 shares $378.82 thousand -16.0%5.2%1.8 $1.30 4/15/2025346,700 shares $269.73 thousand +152.7%6.8%2.5 $0.78 3/31/2025137,200 shares $172.87 thousand +11.7%2.7%3.3 $1.26 3/15/2025122,800 shares $195.25 thousand +14.6%2.8%2 $1.59 2/28/2025107,200 shares $171.52 thousand -3.3%2.4%1.6 $1.60 2/15/2025110,900 shares $206.27 thousand +21.3%2.5%1.4 $1.86 Get the Latest News and Ratings for BCLI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202591,400 shares $166.35 thousand -47.2%2.1%0.9 $1.82 1/15/2025173,000 shares $354.65 thousand +85.4%3.9%1.7 $2.05 12/31/202493,300 shares $211.79 thousand -38.8%2.1%0.8 $2.27 12/15/2024152,400 shares $220.98 thousand +2.8%3.1%1.4 $1.45 11/30/2024148,200 shares $257.87 thousand -14.8%3.0%1.6 $1.74 11/15/2024173,900 shares $210.42 thousand +58.4%3.6%2.3 $1.21 10/31/2024109,800 shares $205.33 thousand -33.8%2.3%1.7 $1.87 10/15/2024165,900 shares $351.71 thousand +33.2%3.4%3.6 $2.12 9/30/2024124,600 shares $28.70 thousand -91.1%2.6%3.6 $0.23 9/15/20241,400,000 shares $394.80 thousand +8.5%N/A3.2 $0.28 8/31/20241,290,000 shares $398.61 thousand -20.4%N/A2.4 $0.31 8/15/20241,620,000 shares $507.38 thousand +51.4%N/A2.9 $0.31 7/31/20241,070,000 shares $366.15 thousand -0.9%N/A1.9 $0.34 7/15/20241,080,000 shares $450.36 thousand -26.5%N/A1.8 $0.42 6/30/20241,470,000 shares $497.60 thousand +65.1%N/A1.9 $0.34 6/15/2024890,600 shares $418.58 thousand -20.5%N/A1 $0.47 5/31/20241,120,000 shares $544.99 thousand -20.6%N/A1.2 $0.49 5/15/20241,410,000 shares $682.44 thousand -32.9%N/A1.4 $0.48 4/30/20242,100,000 shares $792.75 thousand +5.5%N/A2.1 $0.38 4/15/20241,990,000 shares $1.09 million +48.5%N/A2 $0.55 3/31/20241,340,000 shares $756.70 thousand +57.6%N/A1.3 $0.56 3/15/2024850,300 shares $283.06 thousand -20.5%N/A0.6 $0.33 2/29/20241,070,000 shares $392.69 thousand -13.0%N/A0.7 $0.37 2/15/20241,230,000 shares $477.24 thousand -39.4%N/A0.5 $0.39 1/31/20242,030,000 shares $717.20 thousand -15.1%N/A0.8 $0.35 1/15/20242,390,000 shares $781.29 thousand -43.2%N/A0.9 $0.33 12/31/20234,210,000 shares $1.15 million +25.3%N/A1.5 $0.27 12/15/20233,360,000 shares $789.60 thousand -4.0%N/A0.9 $0.24 11/30/20233,500,000 shares $976.50 thousand -7.2%N/A1.1 $0.28 11/15/20233,770,000 shares $689.91 thousand +5.6%N/A1.6 $0.183..2..1.. AI 2.0 ignition (don’t sleep on this) (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 10/31/20233,570,000 shares $546.21 thousand -20.5%9.8%1.9 $0.15 10/15/20234,490,000 shares $763.30 thousand +1.1%12.4%2.6 $0.17 9/30/20234,440,000 shares $888.44 thousand +26.1%12.2%3 $0.20 9/15/20233,520,000 shares $3.39 million +9.3%9.7%9.3 $0.96 8/31/20233,220,000 shares $5.51 million +21.1%9.2%13.4 $1.71 8/15/20232,660,000 shares $4.15 million No Change7.6%11.3 $1.56 7/31/20232,660,000 shares $4.89 million -5.3%8.6%12 $1.84 7/15/20232,810,000 shares $5.54 million +0.4%9.1%12.1 $1.97 6/30/20232,800,000 shares $5.77 million +2.9%9.1%11.7 $2.06 6/15/20232,720,000 shares $7.37 million -5.6%8.8%6.7 $2.71 5/31/20232,880,000 shares $8.21 million +0.4%9.6%7.2 $2.85 5/15/20232,870,000 shares $7.92 million -9.2%9.5%8 $2.76 4/30/20233,160,000 shares $9.13 million +7.9%11.3%7.8 $2.89 4/15/20232,930,000 shares $8.23 million -5.5%10.4%7.3 $2.81 3/31/20233,100,000 shares $10.23 million +29.7%11.0%7.7 $3.30 3/15/20232,390,000 shares $3.87 million +0.8%8.5%10.2 $1.62 2/28/20232,370,000 shares $5.36 million +3.0%8.4%10.6 $2.26 2/15/20232,300,000 shares $5.24 million +18.6%8.1%9.6 $2.28 1/31/20231,940,000 shares $3.53 million -1.5%6.9%7 $1.82 1/15/20231,970,000 shares $2.88 million -3.9%7.0%8.3 $1.46 12/30/20222,050,000 shares $3.36 million -9.3%7.3%8.9 $1.64 12/15/20222,260,000 shares $4.09 million No Change8.0%9.6 $1.81 11/30/20222,260,000 shares $3.73 million -12.4%8.0%8.8 $1.65 11/15/20222,580,000 shares $4.46 million -4.1%9.1%9.8 $1.73 10/31/20222,690,000 shares $9.58 million +10.3%9.5%11.1 $3.56 10/15/20222,440,000 shares $8.49 million +23.2%8.7%10.2 $3.48 9/30/20221,980,000 shares $8.75 million +52.3%7.0%8.9 $4.42 9/15/20221,300,000 shares $5.59 million +68.2%4.6%7.2 $4.30 8/31/2022772,900 shares $2.80 million +36.6%2.7%5.3 $3.62 8/15/2022565,900 shares $1.95 million -5.4%2.0%4.8 $3.45 7/31/2022598,200 shares $1.53 million +3.1%2.1%9.8 $2.56 7/15/2022580,300 shares $1.53 million -9.5%3.2%9.5 $2.64 6/30/2022641,300 shares $1.77 million -0.1%3.6%10.7 $2.76 6/15/2022642,100 shares $1.83 million -4.9%3.6%10.2 $2.85 5/31/2022675,200 shares $1.99 million +5.6%2.4%10.6 $2.94 5/15/2022639,600 shares $1.74 million +6.6%2.3%9.7 $2.72 4/30/2022600,200 shares $1.80 million -2.1%2.1%9.1 $3.00 4/15/2022612,800 shares $1.93 million -8.5%2.2%8.6 $3.15 3/31/2022669,400 shares $2.25 million -8.4%2.4%8.4 $3.36 3/15/2022731,100 shares $2.30 million -0.6%2.6%5.1 $3.15 2/28/2022735,200 shares $2.24 million -7.0%2.6%2.4 $3.05 2/15/2022790,200 shares $2.47 million -22.5%2.8%2.1 $3.12 1/31/20221,020,000 shares $3.18 million -9.7%3.3%2.5 $3.12 1/15/20221,130,000 shares $4.01 million -17.5%3.6%2.7 $3.55 12/31/20211,370,000 shares $5.48 million +11.4%4.4%3.3 $4.00 12/15/20211,230,000 shares $4.05 million +32.1%3.9%3.3 $3.29 11/30/2021931,500 shares $3.54 million +27.1%3.1%4.2 $3.80 11/15/2021732,900 shares $2.23 million -1.4%2.4%4.8 $3.04 10/29/2021743,600 shares $2.16 million -11.5%2.5%6.3 $2.90 10/15/2021839,800 shares $2.59 million -14.4%2.8%5.9 $3.083..2..1.. AI 2.0 ignition (don’t sleep on this) (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 9/30/2021981,000 shares $3.24 million +6.8%3.3%6.6 $3.30 9/15/2021918,700 shares $3.24 million -11.7%3.1%4.1 $3.53 8/31/20211,040,000 shares $3.61 million No Change3.5%4.3 $3.47 8/13/20211,040,000 shares $3.83 million +16.3%3.5%3.5 $3.68 7/30/2021894,200 shares $3.60 million -32.3%3.0%2.7 $4.03 7/15/20211,320,000 shares $4.51 million -5.7%4.4%3.6 $3.42 6/30/20211,400,000 shares $5.32 million -60.9%4.7%3.4 $3.80 6/15/20213,580,000 shares $14.21 million +0.3%11.9%6.3 $3.97 5/28/20213,570,000 shares $12.78 million -18.5%11.9%5.8 $3.58 5/14/20214,380,000 shares $14.10 million +14.7%N/A6 $3.22 4/30/20213,820,000 shares $13.41 million +4.1%N/A4.4 $3.51 4/15/20213,670,000 shares $12.92 million -16.4%N/A3.2 $3.52 3/31/20214,390,000 shares $16.29 million +4.0%N/A3.8 $3.71 3/15/20214,220,000 shares $18.06 million +7.4%N/A3.5 $4.28 2/26/20213,930,000 shares $15.60 million -6.9%N/A3.4 $3.97 2/12/20214,220,000 shares $30.00 million -9.4%N/A3.2 $7.11 1/29/20214,660,000 shares $29.38 million -2.9%N/A3.1 $6.31 1/15/20214,800,000 shares $24.05 million -11.1%N/A3.6 $5.01 12/31/20205,400,000 shares $25.00 million -15.2%N/A4.1 $4.63 12/15/20206,370,000 shares $33.06 million -5.9%N/A4.9 $5.19 11/30/20206,770,000 shares $35.54 million +5.5%N/A5.7 $5.25 11/15/20206,420,000 shares $74.79 million +7.5%N/A6.1 $11.65 10/30/20205,970,000 shares $64.18 million +17.5%N/A10.2 $10.75 10/15/20205,080,000 shares $84.79 million +12.1%N/A8.4 $16.69 9/30/20204,530,000 shares $76.65 million +18.3%N/A8.7 $16.92 9/15/20203,830,000 shares $54.19 million -1.5%N/A6 $14.15 8/31/20203,890,000 shares $49.05 million +8.1%N/A5.5 $12.61 8/14/20203,600,000 shares $47.77 million +2.9%N/A4.8 $13.27 7/31/20203,500,000 shares $47.43 million -20.8%N/A4.8 $13.55 BCLI Short Interest - Frequently Asked Questions What is Brainstorm Cell Therapeutics' current short interest? Short interest is the volume of Brainstorm Cell Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, investors have sold 604,500 shares of BCLI short. 7.91% of Brainstorm Cell Therapeutics' shares are currently sold short. Learn More on Brainstorm Cell Therapeutics' current short interest. What is a good short interest percentage for Brainstorm Cell Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.91% of Brainstorm Cell Therapeutics' floating shares are currently sold short. Is Brainstorm Cell Therapeutics' short interest increasing or decreasing? Brainstorm Cell Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 604,500 shares, an increase of 30.5% from the previous total of 463,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Brainstorm Cell Therapeutics' float size? Brainstorm Cell Therapeutics currently has issued a total of 9,840,000 shares. Some of Brainstorm Cell Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Brainstorm Cell Therapeutics currently has a public float of 7,640,000 shares. How does Brainstorm Cell Therapeutics' short interest compare to its competitors? 7.91% of Brainstorm Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Brainstorm Cell Therapeutics: Aadi Bioscience, Inc. (6.58%), Prelude Therapeutics Incorporated (2.24%), Exicure, Inc. (0.36%), Scilex Holding Company (8.59%), Mural Oncology PLC (1.50%), Lantern Pharma Inc. (3.21%), Mersana Therapeutics, Inc. (10.59%), PepGen, Inc. (4.78%), Acrivon Therapeutics, Inc. (3.45%), Karyopharm Therapeutics Inc. (25.50%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Brainstorm Cell Therapeutics stock? Short selling BCLI is an investing strategy that aims to generate trading profit from Brainstorm Cell Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Brainstorm Cell Therapeutics? A short squeeze for Brainstorm Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCLI, which in turn drives the price of the stock up even further. How often is Brainstorm Cell Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCLI, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Aadi Bioscience Short Interest Data Prelude Therapeutics Short Interest Data Exicure Short Interest Data Scilex Short Interest Data Mural Oncology Short Interest Data Lantern Pharma Short Interest Data Mersana Therapeutics Short Interest Data PepGen Short Interest Data Acrivon Therapeutics Short Interest Data Karyopharm Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCLI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMajor Rollout of Social Security X?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
